Chemiluminescent Immunoassay Analyzer FM-CLA-A100 offers a maximum throughput of 180 tests per hour and processes samples from 10 to 200 μL. It employs magnetic particle separation technology for effective isolation and separation of components. It provides real-time updates, allowing users to continuously monitor test progress. Equipped with safety alarms to ensure smooth operation.
$24,750.00
| Throughput | 180 T/H |
| Sample Volume | 10 to 200 μL |
| Principle | Magnetic particle enzymatic chemiluminescence |
| 1st Result Time | 18 minutes |
| Operation Modes | Random, Batch and STAT |
| Separation Method | Magnetic separation technology |
| Sample Positions | 60 (Each position could be used as an emergency position) |
| Reagent Positions | 25 pcs (2-8 ℃ refrigeration) |
| Incubation Positions | 58 |
| Detection Precision | CV ≤ 5 % |
| Carry-Over Rate | ≤ 10-5 |
| Correlation Coefficient | r ≥ 0.99 |
| Calibration Stability | 28 Days |
| Calibration Type | 6 / 7-point calibration |
| Software | Windows 7/8/10, 32 or 64 bit, Bi-direction, support HL7 protocol, Intuitive User Interface, Intelligent Data Management |
| Interface | TCP/IP Network interface |
| Functions | Liquid level detection, Anti-collision function, Sample barcode scanning, Reagent radio frequency identification, Intelligent alarm prompt. |
| Power Supply | AC 110/220 V, 50/60 Hz |
| Dimensions (W × D × H) | 768 × 771 × 568 mm |
| Packaging Dimension (W × D × H) | 1303 × 873 × 854 mm |
| Net Weight | 94 Kg |
| Gross Weight | 163 Kg |
Fison Chemiluminescent Immunoassay Analyzers are designed to detect diseases by separating and effective isolation, components using magnetic particles. These offer a maximum throughput of 180 tests per hour and process samples from 10 to 200 µL. The analyzers provide real-time updates, allowing users to continuously monitor test progress. They are equipped with safety alarms to ensure smooth operation and triple magnetic separation cleaning technology. Our immunoassay analyzers are used for clinical diagnosis, cancer screening, hormone testing, and drug monitoring.